Merck Boosts Keytruda's Lifespan with New Qlex Version
Pharmaceutical giant Merck has made significant moves to extend the lifecycle of its cancer treatment, Keytruda. The company has launched a new subcutaneous version called Qlex and secured exclusivity for the drug until 2039. This development is expected to boost sales and revenue for Merck in the coming years.
In addition to extending the life cycle of Keytruda, Merck has strengthened its oncology and virology portfolios through recent regulatory approvals and acquisitions. The company acquired Terns and Cidara, expanding its capabilities in these areas. While analyst estimates for long-term earnings per share have improved, the stock's 17% rally since the latest quarterly results suggests that the current valuation is justified.
The analyst maintains a HOLD rating on Merck's stock, citing a less attractive risk-reward balance after the recent price increase. The stock's price-to-earnings ratio for 2030-32 is around 13.5, which may indicate that the current valuation is reasonable given the company's strong innovation and management.